Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials.
Genovese MC, Mysler E, Tomita T, Papp KA, Salvarani C, Schwartzman S, Gallo G, Patel H, Lisse JR, Kronbergs A, Leage SL, Adams DH, Xu W, Marzo-Ortega H, Lebwohl MG. Genovese MC, et al. Among authors: leage sl. Rheumatology (Oxford). 2020 Dec 1;59(12):3834-3844. doi: 10.1093/rheumatology/keaa189. Rheumatology (Oxford). 2020. PMID: 32449924 Free PMC article.
Corrigendum to: Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials.
Genovese MC, Mysler E, Tomita T, Papp KA, Salvarani C, Schwartzman S, Gallo G, Patel H, Lisse JR, Kronbergs A, Leage SL, Adams DH, Xu W, Marzo-Ortega H, Lebwohl MG. Genovese MC, et al. Among authors: leage sl. Rheumatology (Oxford). 2021 Nov 3;60(11):5485. doi: 10.1093/rheumatology/keab566. Rheumatology (Oxford). 2021. PMID: 34549772 Free PMC article. No abstract available.
Ixekizumab Demonstrates Consistent Efficacy Versus Adalimumab in Biologic Disease-Modifying Anti-rheumatic Drug-Naïve Psoriatic Arthritis Patients Regardless of Psoriasis Severity: 52-Week Post Hoc Results from SPIRIT-H2H.
Kristensen LE, Okada M, Tillett W, Leage SL, El Baou C, Sapin C, Bradley AJ, Meszaros G, Dutz JP, de Vlam K. Kristensen LE, et al. Among authors: leage sl. Rheumatol Ther. 2022 Feb;9(1):109-125. doi: 10.1007/s40744-021-00388-8. Epub 2021 Oct 28. Rheumatol Ther. 2022. PMID: 34709605 Free PMC article.
Efficacy and Safety of Ixekizumab Versus Adalimumab in Biologic-naïve Patients With Active Psoriatic Arthritis and Moderate-to-severe Psoriasis: 52-week Results From the Randomized SPIRIT-H2H Trial.
Reich K, Kristensen LE, Smith SD, Rich P, Sapin C, Leage SL, McKenzie R, Schuster C, Riedl E, Gooderham M. Reich K, et al. Among authors: leage sl. Dermatol Pract Concept. 2022 Apr 1;12(2):e2022104. doi: 10.5826/dpc.1202a104. eCollection 2022 May. Dermatol Pract Concept. 2022. PMID: 35646453 Free PMC article.